Colchicine

| Table of contents |
|
2 Pharmacology 3 External links |
History
The colchicine alkaloid was first isolated in 1820 by the two French chemists P.S. Peletier and J. Caventon (Pelletier PS, Caventon J. Ann Chim Phys 1820;14:69).
Colchinum extract was first described as a treatment for gout in De Materia Medica of Padanius Dioscorides.
It was later identified as a tricyclic alkaloid and its pain relieving and anti-inflammatory effects for gout were linked to it binding with the protein tubulin.
Pharmacology
Biological function
The molecular formula of colchicine is C22H25NO6. Structural chemical names are:
- (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo [alpha] heptalen-7-yl)acetamide;
- N-(5,5,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[alpha]heptalen-7-yl)acetamide.
Colchicine as medicine
Colchicine is FDA-approved for the treatment of gout and also for familial Mediterranean fever, amyloidosis, and scleroderma. Side-effects include gastro-intestinal upset and neutropenia. Starting the drug early during an attack of gout can exacerbate the symptoms. High doses can also damage bone marrow and lead to anemia. It's not used in the treatment of cancer, as the dose required would lead to intolerable side-effects.
Toxicity
Poisoning resembles intoxication with arsenic: symptoms start 2 to 5 hours after the toxic dose has been ingested and include burning in the mouth and throat, fever, vomiting, diarrhea, abdominal pain and kidney failure. Death from respiratory failure can follow. There is no antidote.
Laboratory use
In laboratory setting colchicine is also used for inducing polyploidy in plant cells during cellular division.
External links